Good morning, everyone, and how are you today? We are doing just fine, thank you, despite a creaky laptop that seems to require more cups of stimulation than we do. Nonetheless, we are forging ahead with plans to hunt for interesting items and making new contacts. Meanwhile, here is the latest menu of tidbits to help you with your own progress today. We hope the journey goes well and, as always, do keep in touch …

Nearly 30 drug makers have taken steps to raise U.S. prices of their medicines in January, ending a self-declared halt to increases made under pressure from the Trump administration, according to Reuters. Twenty-eight companies filed notifications with California agencies in early November disclosing that they planned to raise prices in 60 days or longer. Under a state law passed last year, companies are required to notify payers in California if they intend to raise the U.S. list price on any drug by more than 16 percent over a two-year period.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy